Editor Profile
Dr. Mehmet Akif BUYUKBESE, M.D.
Professor
Present
Gaziantep Islam Science and Technology University (GİBTÜ)
Gaziantep
Turkey
Mehmet Akif BUYUKBESE
MD, Consultant Diabetologist, Prof of Internal Medicine.
Gaziantep Islam Science & Technology University
Gaziantep-TÜRKİYE
+90-532-5456670
h-index: 15
akif_buyukbese@yahoo.com
MD, Consultant Diabetologist, Prof of Internal Medicine at Gaziantep Islam Science and Technology University in Türkiye.
Although credentials are from Istanbul University, Türkiye; has USMLE certificate from USA where he was offered endocrinology fellowship at Wayne State University, Detroit, MI.
Had clinical observership at Indian Medical Center in AZ, MD Anderson & Univ of TX at Houston and Albert Einstein College of Medicine in NY Diabetes & Endocrinology Programs. Worked at Kronos Longevity Research Institute in Phx, AZ in USA and Univ of Leicester in UK.
Gave Diabetes lectures through EU Erasmus Programs at Goettingen Univ, Germany.
Awarded Diabetes service prize several times from Turkish Diabetes Foundation for GAPDIAB (Southeast Türkiye Rural Community Diabetes Education) Project.
Served as Kahramanmaras City Coordinator of Presidency of Türkiye Type 1 Diabetes Peer Project.
Board Member of Trustees of Turkish Diabetes Foundation.
Currently active member of study group of International Diabetes Federation, Diabetes & Ramadan (IDF-DaR) Alliance.
Worked actively in recent (2026) and previous published (2016, 2021) DaR guidelines booklets.
Also members of International Diabetes Federation (IDF), European Society of Cardiology, Turkish Society of Internal Medicine (TIHUDUM) & Internal Medicine Specialists Association (DAHUDER)
In the past, involved in Turkish Society of Cardiology Marmara Region (outside Istanbul) Adult Patients Prospective Cardiac Risk Factors Study (TEKHARF).
Formerly founded internal Medicine department in the faculty in Türkiye where he served as department of internal medicine head for 6 years.
Currently has more than 200 publications in both national & international journals & 6 books (4 of them as chapter writer, the rest 2 as co-editors, all on diabetes), also, 1 chapter translater (Joslin’s Diabetes Mellitus).
- Diabetes Mellitus & Endocrinology
- Metabolic Syndrome & Cardiovascular Risk
- Oxidative Stress & Antioxidants
- Infectious Diseases
- Dermatology & Ocular Disorders in Diabetes
- Public Health & Lifestyle Medicine
- Buyukbese MA. Kidneys with diabetes and Ramadan intermittent fasting. J Nephrol Endocrinol Res. 2026;6(1):1‑3. doi:10.47363/JONE/2025(5)141.
- Hassanein M, Hafidh K, Ahmedani MY, Odhaib SA, Shaltout I, Batais MA, Rosandi R, Fariduddin M, Alabbood M, Buyukbese MA, Voon TC, Rachid M, Al‑amoudi R. Effect of different insulin regimens on individuals with type 2 diabetes during Ramadan fasting in the DAR global surveys of 2020 and 2022. J Diabetes Endocr Pract. 2025. doi:10.1055/s‑0045‑1811580.
- Hassanein M, Malek R, AlSifri S, Sahay RK, Buyukbese MA, Djaballah K, Melas‑Melt M, Shaltout I. Safety and effectiveness of concomitant iGlarLixi and SGLT‑2i use in people with T2D during Ramadan fasting: a SoliRam study subanalysis. Diabetes Ther. 2024. doi:10.1007/s13300‑024‑01642‑2.
- Hassanein M, Ahmedani MY, Shaltout I, Alabbood M, Buyukbese MA, Hafidh K, Shaikh S, El Toony LF, Sahay RK, Batais MA, Alfadhli E, Uddin MF, Alfadhly AF, Shenoy MT, Salleh A, Alzaman N, Sheshah E, Kebira B, Alamoudi R, Hussein Z. Ramadan fasting among adults with type 2 diabetes in five geographically different regions of the world: the DAR 2020 global survey. Diabetes Epidemiol Manag. 2024;16:100229. doi:10.1016/j.deman.2024.100229.
- Hassanein M, Malek R, Shaltout I, Sahay RK, Buyukbese MA, Djaballah K, Pilorget V, Coudert M, Al Sifri S; SoliRam Study Investigators. Real‑world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: the SoliRam observational study. Diabetes Metab Syndr. 2023;17(2):102707. doi:10.1016/j.dsx.2023.102707.
- Hassanein M, Buyukbese MA, Malek R, Pilorget V, Naqvi M, Berthou B, Shaltout I, Kumar Sahay R. Real‑world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: the observational ORION study. Diabetes Res Clin Pract. 2020;166:108189. doi:10.1016/j.diabres.2020.108189.
- Buyukbese MA, Pamuk ON, Yurekli OA, Yesil N. Effect of fibromyalgia on bone mineral density in patients with fibromyalgia and rheumatoid arthritis. J Postgrad Med. 2013;59(2):106‑109. doi:10.4103/0022‑3859.113825.
- Diler A, Yilmaztürk G, Akalin N, Fenkçi S, Buyukbese MA. Reducing variability of HbA1c results among methods/laboratories in Turkey. 2nd Int Congr Prediabetes Metab Syndr. Barcelona, Spain. Apr 25‑28, 2007. (Poster).
- Yilmaz MT, Karadeniz S, Sargin M, Buyukbese MA, Sengul A. Chronic complications in long‑term type 1 and type 2 diabetic patients with poor glycemic control: TUDIC Results‑1. World Congr Controversies Obesity Diabetes Hypertension. Berlin, Germany. Oct 26‑29, 2006. (Poster).
- Buyukbese MA, Cetinus E, Cetinkaya A, Aras S. Ferritin levels in postmenopausal women do not seem to play a significant role in osteoporosis. South Med J. 2005;98(8):845. doi:10.1097/01.smj.0000172784.09331.4e.
- Buyukbese MA, Cetinkaya A, Kocabas R, Guven A, Tarakcioglu M. Leptin levels in obese women with and without type 2 diabetes mellitus. Mediators Inflamm. 2004;13(5‑6):321‑325. doi:10.1080/09629350400008828.
- Tringham JR, Buyukbese MA, Davies MJ. Prevalence of metabolic syndrome in patients with screen‑detected type 2 diabetes and impaired glucose tolerance. Diabetologia. 2004;47(Suppl 1):115. (Poster, EASD Munich).
- Ozcan S, Buyukbese MA. Southeastern Anatolia Diabetes Project (GAPDIAB Project). 9th Annual Conf Federation of European Nurses in Diabetes, EASD Munich. Sep 3‑4, 2004. (Oral).